Advances in Biomarker-Based Diagnostics: From Discovery to Clinical Application

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensors and Healthcare".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 1435

Special Issue Editor


E-Mail Website
Guest Editor
1. Centro De Investigaciones Biomédicas (CINBIO), Universidade de Vigo, 36310 Vigo, Spain
2. Department of Biotechnology, School of Engineering and Applied Sciences, Bennett University, Greater Noida, UP, India
Interests: microfluidic bio-sensing; point-of-care diagnostics; microfluidic devices; lab-on-chip and molecular biosensing
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, "Advances in Biomarker-Based Diagnostics: From Discovery to Clinical Application", showcases recent innovations in the discovery, validation, and clinical translation of molecular biomarkers. Biomarkers—spanning nucleic acids, proteins, metabolites, and extracellular vesicles—are increasingly central to precision diagnostics, offering insights into disease onset, progression, prognosis, and therapeutic responsiveness.

The integration of high-throughput omics technologies (genomics, proteomics, metabolomics), bioinformatics pipelines, and machine learning models has accelerated the identification of clinically actionable biomarkers. In parallel, advancements in biosensing platforms and microfluidic lab-on-a-chip systems are enabling the rapid, multiplexed, and minimally invasive detection of biomarkers from complex biological matrices, such as blood, saliva, and urine.

This Special Issue emphasizes the translational continuum from biomarker discovery and analytical validation to assay development, clinical performance evaluation, and regulatory considerations aligned with FDA, CLIA, and ISO standards. Contributions cover a spectrum of diagnostic modalities including liquid biopsies (e.g., ctDNA, exosomes), immunosensors, electrochemical biosensors, and microfluidic point-of-care devices.

Applications are illustrated across oncology, infectious diseases, neurodegenerative disorders, and cardiovascular diagnostics. Additionally, this Issue explores the challenges of standardization, reproducibility, and data integration.

By bridging molecular science with engineering and clinical practice, it aims to advance the development of next-generation diagnostics for personalized and predictive medicine. The scope of the Special Issue is broad and covers the following specified areas:

  1. Biomarker Discovery and Multi-Omics Approaches
    – Identification and validation of novel biomarkers using genomics, proteomics, metabolomics, and integrative omics strategies.
  2. Biosensors and Microfluidic Diagnostic Platforms
    – Development and application of biosensing technologies, lab-on-a-chip systems, and microfluidic devices for rapid and sensitive biomarker detection.
  3. Liquid Biopsy and Non-Invasive Diagnostics
    – Advances in ctDNA, circulating tumor cells, exosomes, and other minimally invasive sampling methods for disease detection and monitoring.
  4. AI and Computational Tools in Biomarker Interpretation
    – Use of machine learning, deep learning, and bioinformatics to analyze biomarker data and support clinical decision-making.
  5. Clinical Applications Across Disease Areas
    – Implementation of biomarker diagnostics in oncology, infectious diseases, neurology, cardiovascular diseases, and autoimmune disorders.
  6. Regulatory, Translational, and Ethical Considerations
    – Clinical assay development, standardization, regulatory pathways (FDA, CE, CLIA), and ethical challenges in biomarker deployment.

Dr. Krishna Kant
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarker
  • diagnostics
  • bio-sensing
  • microfluidic sensing
  • smart sensor
  • multiplexed sensor
  • lab-on-chip

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 3687 KB  
Communication
A Label-Free G-Quadruplex/Thioflavin T Fluorescent Sensor for ClO Detection: Implications for Stress-Induced Hypertension Biomarker Analysis
by Jianting Liu, Yaru Zhao, Linfang Zhang, Haisheng Liu and Guosong Zhang
Biosensors 2026, 16(3), 169; https://doi.org/10.3390/bios16030169 - 18 Mar 2026
Viewed by 413
Abstract
The objective of this study is to develop a label-free fluorescent sensor for the quantitative detection of hypochlorite ions (ClO) and validate its applicability in biological samples, particularly exploring the potential of ClO as a biomarker for stress-induced hypertension (SIH). [...] Read more.
The objective of this study is to develop a label-free fluorescent sensor for the quantitative detection of hypochlorite ions (ClO) and validate its applicability in biological samples, particularly exploring the potential of ClO as a biomarker for stress-induced hypertension (SIH). Male Sprague-Dawley rats (8 weeks old, 250–300 g) were used to establish the SIH model. A guanine-rich (G-rich) signal DNA sequence (S-DNA) was rationally designed, with a ClO-responsive phosphorothioate (PS) moiety integrated into the probe architecture. In the absence of ClO, the S-DNA folds into a stable G-quadruplex structure, which specifically binds to ThT and triggers a significant enhancement of the dye’s fluorescence intensity. Upon introduction of ClO, the specific hydrolysis reaction between the PS moiety and ClO induces cleavage of the S-DNA into two discrete fragments, thereby abrogating G-quadruplex formation and resulting in a remarkable quenching of ThT fluorescence. This proposed method exhibits excellent anti-interference capability against other reactive oxygen species (ROS) and achieves a low detection limit of 41.2 nM for ClO. Furthermore, this strategy was successfully applied to the quantitative determination of endogenous ClO in human cells and the plasma of stress-induced hypertensive (SIH) rats, highlighting its substantial potential for clinical and physiological research. Full article
Show Figures

Figure 1

17 pages, 2365 KB  
Article
Proof of Concept for Tumor Mutational Burden Prediction Through Biophysical Analysis Based on UHF-Dielectrophoresis
by Héloïse Daverat, Nina Blasco, Sandrine Robert, Amandine Rovini, Claire Dalmay, Fabrice Lalloué, Arnaud Pothier, Karine Durand and Thomas Naves
Biosensors 2026, 16(3), 134; https://doi.org/10.3390/bios16030134 - 25 Feb 2026
Viewed by 685
Abstract
Tumor Mutational Burden (TMB) is a critical biomarker used to determine patient eligibility for immunotherapy with immune checkpoint inhibitors. However, its gold-standard assessment via whole exome sequencing is limited by high costs, technical complexity, and lengthy processing times. To address these challenges, we [...] Read more.
Tumor Mutational Burden (TMB) is a critical biomarker used to determine patient eligibility for immunotherapy with immune checkpoint inhibitors. However, its gold-standard assessment via whole exome sequencing is limited by high costs, technical complexity, and lengthy processing times. To address these challenges, we investigated whether Ultra-High-Frequency (UHF) electromagnetic wave sensing could serve as an alternative method for evaluating TMB. We analyzed the dielectrophoresis crossover frequency spectrum and corresponding electromagnetic signature (EMS) of cancer cells using a lab-on-a-chip biosensor that integrates microfluidics with dielectrophoresis-based electro-manipulation. Across seven solid tumor cell lines exhibiting diverse TMB levels, EMS exhibited an upward shift correlated with higher TMB, suggesting a relationship between mutational load and electromagnetic behavior. To further explore this connection, we artificially increased the somatic variant burden by exposing cells to the mutagen N-ethyl-N-nitrosourea (ENU). EMS measurements reliably detected the induced increase in variant load in ENU-treated cells. Overall, these findings demonstrate that EMS can detect both intrinsic TMB differences and experimentally induced increases in mutational burden, enabling refined categorization of cancer cells. Although further validation is required, this work lays the foundation for developing complementary, rapid, and accessible tools to support cancer cell stratification and guide immunotherapy decision-making. Full article
Show Figures

Graphical abstract

Back to TopTop